World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression.
These practice guidelines for the biological, mainly pharmacological treatment of bipolar depression were developed by an international task force of the World Federation of Societies of Biological Psychiatry (WFSBP). Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of bipolar depression. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, and from recent proceedings of key conferences and various national and international treatment guidelines. Their scientific rigor was categorised into four levels of evidence (A-D). As these guidelines are intended for clinical use, the scientific evidence was not only graded, but also commented on by the experts of the task force to ensure practicability.
Grunze
Heinz
H
Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstrasse 7, 80336 Munich, Germany. grunze@psy.med.uni-muenchen.de
Kasper
Siegfried
S
Goodwin
Guy
G
Bowden
Charles
C
Baldwin
David
D
Licht
Rasmus
R
Vieta
Eduard
E
Möller
Hans-Jürgen
HJ
D000928:Antidepressive Agents / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D001689:Biological Psychiatry; D001714:Bipolar Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D002220:Carbamazepine / Q000627:therapeutic use; D004565:Electroconvulsive Therapy / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D007391:International Cooperation; D000077213:Lamotrigine; D016651:Lithium Carbonate / Q000627:therapeutic use; D014227:Triazines / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use
D000928:Antidepressive Agents; D018692:Antimanic Agents; D014227:Triazines; D016651:Lithium Carbonate; D002220:Carbamazepine; D014635:Valproic Acid; D000077213:Lamotrigine